Cargando…
Chimeric antigen receptor T‑cell therapy—a hematological success story
Chimeric antigen receptor (CAR) T cells are genetically engineered autologous cells that express an activating receptor targeted towards one or more tumoral antigens. After ex vivo production and re-infusion, they are able to proliferate in the host and to recognize and kill tumor cells. Together wi...
Autores principales: | Wohlfarth, Philipp, Worel, Nina, Hopfinger, Georg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006225/ https://www.ncbi.nlm.nih.gov/pubmed/29983827 http://dx.doi.org/10.1007/s12254-018-0409-x |
Ejemplares similares
-
CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
por: Hopfinger, Georg, et al.
Publicado: (2019) -
Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015) -
Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
por: Yang, Zhihuan, et al.
Publicado: (2023) -
Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022) -
Chimeric Antigen Receptor Therapy for B-cell Malignancies
por: Porter, David L, et al.
Publicado: (2011)